Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

5187 - The use of HPV16-E5, EGFR and pEGFR as prognostic biomarkers for oropharyngeal cancer patients

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Tumour Site

Head and Neck Cancers

Presenters

Miren Taberna

Citation

Annals of Oncology (2018) 29 (suppl_8): viii372-viii399. 10.1093/annonc/mdy287

Authors

M. Taberna1, M. Torres2, M. Alejo3, M. Mena2, S. Tous2, S. Marquez2, M.A. Pavon2, X. Leon4, J. Garcia4, M. Guix5, R. Hijano6, T. Bonfill7, A. Aguilà8, A. Lozano9, R. Mesia Nin10, L. Alemany2, I.G. Bravo11

Author affiliations

  • 1 Medical Oncology, Institut Català d'Oncologia Hospital Duran i Reynals, 08907 - Barcelona/ES
  • 2 Prec, Institut Català d'Oncologia Hospital Duran i Reynals, Barcelona/ES
  • 3 Pathology, Hospital General de Hospitalet, 08908 - L'hospitalet de Llobregat/ES
  • 4 Otorhinolaryngology Department, Hospital de Sant Pau, Barcelona/ES
  • 5 Medical Oncology, Hospital del Mar, Barcelona/ES
  • 6 Otorhinolaryngology Department, Hospital del Mar, Barcelona/ES
  • 7 Medical Oncology, Hospital Parc Taulí, 28023 - Barcelona/ES
  • 8 Otorhinolaryngology Department, Hospital Parc Taulí, 28023 - Barcelona/ES
  • 9 Radiation oncology, Institut Catala de Oncologia, 8907 - Barcelona/ES
  • 10 Medical Oncology, Catalan Institute of Oncology (ICO Badalona), Hospital Germans Trias i Pujol, 08916 - Badalona/ES
  • 11 Laboratory Mivegec, National Center for Scientific Research (UMR CNRS IRD UM), Montpellier/FR

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 5187

Background

HPV-related oropharyngeal cancer (OPC) patients have favorable prognosis, but around 20% fail to treatment. The HPV16-E5 oncoprotein increases recycling of activated epidermal growth factor receptor (EGFR) to the cell surface, enhancing factor signal transduction. Our aim was to evaluate viral HPV16-E5 oncogene expression as well as EGFR and its activated form, phosphorylated EGFR (pEGFR), protein levels as biomarkers for clinical outcome in a retrospective cohort of OPC patients.

Methods

Formalin-fixed-paraffin-embedded OPC were collected from pathology archives. Samples containing HPV-DNA were further subject to HPV E6*I mRNA detection and p16INK4a immunohistochemistry (IHC). HPV16-positive cases were evaluated for HPV16-E5 (RT-PCR) and EGFR/pEGFR (IHC). A stratified random sample of HPV-negative samples was evaluated for EGFR/pEGFR. Overall survival (OS) and disease-free survival (DFS) estimates were assessed.

Results

Among the 788 OPC patient samples from a retrospective cohort, 54 where double positive for HPV16-DNA and p16INK4a. HPV16-E5 expression was found in 41 samples (77.4%). Expression of EGFR was observed in 37.7% vs 70.8% HPV16-positive and HPV-negative samples, respectively; (adjusted Odds Ratio (OR) 0.15[95%Confident Interval (CI):0.04-0.56]). Expression of pEGFR followed an inverse pattern with 39.6% and 24.9% detection in HPV16-positive and HPV-negative samples, respectively; (adjusted OR 1.58[0.48-5.17]). Within HPV16-positive cases, no association between HPV16-E5 and EGFR or pEGFR was observed. The combination of HPV status and EGFR or pEGFR expression were predictors of OS and DFS.

Conclusions

HPV16-E5 is highly expressed on HPV16-positive OPCs. Interestingly, HPV16-positive cases expressed more pEGFR while HPV-negative cases expressed significantly more EGFR. The combinations of HPV status and EGFR or pEGFR expression are useful biomarkers for prognosis outcome in OPC patients.

Clinical trial identification

Legal entity responsible for the study

Institut Català d'Oncologia.

Funding

This work was supported by a grants from “Ayudas Merck Serono Investigación_Salud 2000” , Instituto de Salud Carlos III-ISCIII (Spanish Government) cofunded by FEDER funds / European Regional Development Fund (ERDF) - a way to build Europe (References: PI1102096, PI1401918, PI1500500, PI1501205, RD12/0036/0056, CIBERESP, CIBERONC), Agència de Gestió d’Ajuts Universitaris i de Recerca (2014SGR756; 2014SGR1077), Beca de recerca clínica 2016 de l'Acadèmia de Ciències Mèdiques de Catalunya i Balears, Beca PERIS-2016-2020 Pla Estratègic de Recerca en Investigacions Sanitàries (SLT002/16/00404), Asociación Española Contra el Cáncer (personal grant to LA), Rio Hortega-SEOM (ISCIII-Spanish Society of Medical Oncology) (personal grant to MT).

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.